

# Global estimates of human papillomavirus vaccination level: a pooled analysis

The Lancet Global Health

4, e453-e463

DOI: [10.1016/s2214-109x\(16\)30099-7](https://doi.org/10.1016/s2214-109x(16)30099-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Reaching women in the Peruvian Andes through cervical cancer screening campaigns: assessing attitudes of stakeholders and patients. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2107-2116.	0.8	13
2	Balancing the cost-benefit equation for cervical cancer prevention: a moving target. <i>Lancet Public Health</i> , The, 2016, 1, e42-e43.	4.7	2
3	HPV vaccination intention among male clients of a large STI outpatient clinic in Amsterdam, the Netherlands. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 178-184.	4.5	10
4	Global disparities in HPV vaccination. <i>The Lancet Global Health</i> , 2016, 4, e428-e429.	2.9	5
5	Biomedical technologies for the prevention of sexually transmitted infections and HIV for adolescent girls and young women. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016, 110, 499-501.	0.7	4
6	Cancer control-A global perspective. <i>European Journal of Cancer Care</i> , 2017, 26, e12654.	0.7	8
7	Preventing human papillomavirus-related cancers: Are we all in this together. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 576.e1-576.e5.	0.7	7
8	Parents' views of including young boys in the Swedish national school-based HPV vaccination programme: a qualitative study. <i>BMJ Open</i> , 2017, 7, e014255.	0.8	24
9	Realistic fear of cervical cancer risk in Japan depending on birth year. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1700-1704.	1.4	34
10	Cervical cancer prevention in upper middle-income countries. <i>Preventive Medicine</i> , 2017, 98, 36-38.	1.6	8
11	High-risk human papillomavirus seroprevalence in men and women of six different ethnicities in Amsterdam, the Netherlands: The HELIUS study. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 57-65.	4.5	7
12	Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations. <i>Oncology Letters</i> , 2017, 13, 2495-2501.	0.8	15
13	Human papillomavirus-associated oropharyngeal cancer: Prioritizing preventive policies in males. <i>Oral Oncology</i> , 2017, 69, 129-130.	0.8	1
14	HPV vaccines - A review of the first decade. <i>Gynecologic Oncology</i> , 2017, 146, 196-204.	0.6	304
15	Mapping information exposure on social media to explain differences in HPV vaccine coverage in the United States. <i>Vaccine</i> , 2017, 35, 3033-3040.	1.7	195
16	Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. <i>Vaccine</i> , 2017, 35, 3922-3929.	1.7	21
17	Worldwide burden of cancer attributable to HPV by site, country and HPV type. <i>International Journal of Cancer</i> , 2017, 141, 664-670.	2.3	1,414
18	Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review. <i>International Journal of Cancer</i> , 2017, 141, 437-446.	2.3	127

#	ARTICLE	IF	CITATIONS
19	Considerations for HPV primary screening in lower-middle income countries. <i>Preventive Medicine</i> , 2017, 98, 39-41.	1.6	9
20	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 336-344.	1.9	20
21	Aluminium adjuvants used in vaccines versus placebo or no intervention. <i>The Cochrane Library</i> , 2017, , .	1.5	8
22	Burden of HPV-caused cancers in Denmark and the potential effect of HPV-vaccination. <i>Vaccine</i> , 2017, 35, 5939-5945.	1.7	8
23	Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. <i>Vaccine</i> , 2017, 35, 6329-6335.	1.7	9
24	The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 47-56.	1.0	50
25	Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings. <i>Cancer Medicine</i> , 2017, 6, 2008-2014.	1.3	22
26	Ending cervical cancer: A call to action. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 4-6.	1.0	21
27	Optimizing secondary prevention of cervical cancer: Recent Advances and future challenges. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 15-19.	1.0	39
28	Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope. <i>Npj Vaccines</i> , 2017, 2, 6.	2.9	4
29	Determinants of Human Papillomavirus Vaccination Intention Among Female Sex Workers in Amsterdam, the Netherlands. <i>Sexually Transmitted Diseases</i> , 2017, 44, 756-762.	0.8	4
30	Progress in HPV vaccination in low- and lower-middle-income countries. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 7-14.	1.0	61
31	Advocacy, communication, and partnerships: Mobilizing for effective, widespread cervical cancer prevention. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 57-62.	1.0	11
32	Global Perinatal Nursing Research. <i>Journal of Perinatal and Neonatal Nursing</i> , 2017, 31, 191-194.	0.5	1
33	Intrauterine Device Use and Cervical Cancer Risk. <i>Obstetrics and Gynecology</i> , 2017, 130, 1226-1236.	1.2	55
34	Strengthening global vaccine access for adolescents and adults. <i>Vaccine</i> , 2017, 35, 6823-6827.	1.7	15
35	Maximizing the Impact of Human Papillomavirus Vaccination. <i>Clinical Infectious Diseases</i> , 2017, 65, 890-892.	2.9	0
36	On the implications of desexualizing vaccines against sexually transmitted diseases: health policy challenges in a multicultural society. <i>Israel Journal of Health Policy Research</i> , 2017, 6, 30.	1.4	18

#	ARTICLE	IF	CITATIONS
37	The global burden of women's cancers: a grand challenge in global health. <i>Lancet</i> , The, 2017, 389, 847-860.	6.3	666
38	Women's cancers: shining a light on a neglected health inequity. <i>Lancet</i> , The, 2017, 389, 771-773.	6.3	20
39	Human papillomavirus (HPV): making the case for "Immunisation for All". <i>Oral Diseases</i> , 2017, 23, 726-730.	1.5	23
40	The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation. <i>Journal of Infectious Diseases</i> , 2017, 216, 1205-1209.	1.9	28
41	Pharmacists' Attitudes and Perceived Barriers to Human Papillomavirus (HPV) Vaccination Services. <i>Pharmacy (Basel, Switzerland)</i> , 2017, 5, 45.	0.6	24
42	Why Human Papillomavirus Acute Infections Matter. <i>Viruses</i> , 2017, 9, 293.	1.5	49
43	Attitudes towards Human Papilloma Virus Vaccination in the Latin American Andean Region. <i>Healthcare (Switzerland)</i> , 2017, 5, 55.	1.0	5
44	Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. <i>Frontiers in Immunology</i> , 2017, 8, 689.	2.2	55
45	Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain. <i>Virology Journal</i> , 2017, 14, 214.	1.4	4
46	The case for integrated human papillomavirus vaccine and HIV prevention with broader sexual and reproductive health and rights services for adolescent girls and young women. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2017, 111, 141-143.	0.7	5
47	Human Papillomavirus Vaccination Rates in Young Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2017, 35, 3582-3590.	0.8	44
48	Screening to Prevent Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 1250-1252.	0.8	14
49	Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. <i>International Journal of Cancer</i> , 2018, 143, 317-323.	2.3	15
50	Global human papilloma virus vaccine implementation: An update. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 989-997.	0.6	27
51	Pricing of HPV Vaccines in Europe: Back to the Future?. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 275-277.	1.0	2
52	No Vacillation on HPV Vaccination. <i>Cell</i> , 2018, 172, 1163-1167.	13.5	20
53	Factors influencing intention to obtain the HPV vaccine in South East Asian and Western Pacific regions: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 3640.	1.6	38
54	Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. <i>International Journal of Epidemiology</i> , 2018, 47, 634-641.	0.9	18

#	ARTICLE	IF	CITATIONS
55	Opportunities and challenges for human papillomavirus vaccination in cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 240-254.	12.8	224
56	Who calls the shots? The ethics of adolescent self-consent for HPV vaccination. <i>Journal of Medical Ethics</i> , 2018, 44, 531-535.	1.0	17
57	Access to cancer care in Colombia, a middle-income country with universal health coverage. <i>Journal of Cancer Policy</i> , 2018, 15, 104-112.	0.6	33
58	Parental perspective on human papillomavirus (HPV) vaccination in Serbia: Knowledge, attitudes and practice. <i>Sexual and Reproductive Healthcare</i> , 2018, 16, 192-198.	0.5	13
59	Parents' uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies. <i>BMJ Open</i> , 2018, 8, e019206.	0.8	152
60	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 205-212.	3.0	71
61	Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies. <i>Vaccine</i> , 2018, 36, 4774-4782.	1.7	103
62	HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. <i>Aids</i> , 2018, 32, 795-808.	1.0	238
63	Social determinants of community-level human papillomavirus vaccination coverage in a school-based vaccination programme. <i>Sexually Transmitted Infections</i> , 2018, 94, 248-253.	0.8	15
64	High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women. <i>Journal of Infectious Diseases</i> , 2018, 217, 1579-1589.	1.9	50
65	Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 63-74.	4.5	22
66	Therapeutic vaccines for high-risk HPV-associated diseases. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 63-74.	4.5	163
67	Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures. <i>Antiviral Research</i> , 2018, 150, 164-173.	1.9	8
68	The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 92-97.	2.0	53
69	Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. <i>Gynecologic Oncology</i> , 2018, 148, 342-348.	0.6	17
70	Eradicating HPV-Associated Cancer Through Immunization: A Glass Half Full. <i>Viral Immunology</i> , 2018, 31, 80-85.	0.6	3
71	Assessing the acceptability of incentivising HPV vaccination consent form return as a means of increasing uptake. <i>BMC Public Health</i> , 2018, 18, 382.	1.2	11
72	Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. <i>Expert Review of Vaccines</i> , 2018, 17, 395-409.	2.0	19

#	ARTICLE	IF	CITATIONS
73	Options for design of real-world impact studies of single-dose vaccine schedules. <i>Vaccine</i> , 2018, 36, 4816-4822.	1.7	11
74	Status of HPV vaccine introduction and barriers to country uptake. <i>Vaccine</i> , 2018, 36, 4761-4767.	1.7	153
75	Human papillomavirus vaccination coverage in Luxembourg – Implications of lowering and restricting target age groups. <i>Vaccine</i> , 2018, 36, 2411-2416.	1.7	6
76	Cervical screening in HPV-vaccinated populations. <i>Climacteric</i> , 2018, 21, 227-234.	1.1	8
77	Rural distribution of human papilloma virus in low- and middle-income countries. <i>Experimental and Molecular Pathology</i> , 2018, 104, 146-150.	0.9	8
78	The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada. <i>Journal of Medical Virology</i> , 2018, 90, 592-598.	2.5	12
79	College women, HPV genotyping and sexual behavior before HPV vaccination: Results from samples stored for a long time. <i>Journal of Infection and Public Health</i> , 2018, 11, 286-289.	1.9	8
80	Epidemiology and burden of HPV-related disease. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 14-26.	1.4	323
81	Impact of a website based educational program for increasing vaccination coverage among adolescents. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 961-968.	1.4	11
82	The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. <i>Trends in Microbiology</i> , 2018, 26, 158-168.	3.5	272
83	Factors involved in human papillomavirus (HPV) vaccine hesitancy among women in the South-East Asian Region (SEAR) and Western Pacific Region (WPR): A scoping review. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 124-133.	1.4	30
84	Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 42-58.	1.4	72
85	Manifesto for global women's health. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 3-4.	12.5	2
86	Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006–2014. <i>American Journal of Public Health</i> , 2018, 108, 112-119.	1.5	45
87	Issues of Awareness Related to Human Papillomavirus Infection Positivity Among US Adult Men. <i>JAMA Oncology</i> , 2018, 4, 424.	3.4	0
88	Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. <i>Journal of Virology</i> , 2018, 92, .	1.5	26
89	HPV Vaccination: Increase Uptake Now to Reduce Cancer. <i>American Journal of Public Health</i> , 2018, 108, 23-24.	1.5	0
90	Association Between Risky Sexual Behavior and Cervical Cancer Screening Among Women in Kenya: A Population-Based Study. <i>Journal of Community Health</i> , 2018, 43, 238-247.	1.9	3

#	ARTICLE	IF	CITATIONS
91	Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. <i>Vaccine</i> , 2018, 36, 5416-5423.	1.7	39
92	Who Will Benefit From Expanding HPV Vaccination Programs to Boys?. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky076.	1.4	7
93	Toward the World Code Against Cancer. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	6
94	Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial. <i>BMJ Open</i> , 2018, 8, e020484.	0.8	38
95	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
96	Lack of school requirements and clinician recommendations for human papillomavirus vaccination. <i>Journal of Public Health Research</i> , 2018, 7, 1324.	0.5	7
97	Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention. <i>Expert Review of Vaccines</i> , 2018, 17, 1093-1104.	2.0	11
98	Low coverage of HPV vaccination in the national immunization programme in Brazil: Parental vaccine refusal or barriers in health-service based vaccine delivery?. <i>PLoS ONE</i> , 2018, 13, e0206726.	1.1	46
99	Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 1156-1164.	0.5	8
100	Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky045.	1.4	115
101	Reaching 80% human papillomavirus vaccination prevalence by 2026: How many adolescents need to be vaccinated and what are their characteristics?. <i>Cancer</i> , 2018, 124, 4720-4730.	2.0	4
102	Human Papillomavirus Vaccines: Successes and Future Challenges. <i>Drugs</i> , 2018, 78, 1385-1396.	4.9	27
103	Human papillomavirus knowledge, beliefs, and behaviors: A questionnaire adaptation. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 230, 103-108.	0.5	10
104	Too many women are dying from cervix cancer: Problems and solutions. <i>Gynecologic Oncology</i> , 2018, 151, 547-554.	0.6	65
105	Population-level sexual behaviours in adolescent girls before and after introduction of the human papillomavirus vaccine (2003–2013). <i>Cmaj</i> , 2018, 190, E1221-E1226.	0.9	16
106	The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors. <i>Frontiers in Immunology</i> , 2018, 9, 1914.	2.2	26
107	HPV Vaccination Recommendation Practices among Adolescent Health Care Providers in 5 Countries. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2018, 31, 575-582.e2.	0.3	4
108	Intersectional nativity and racial/ethnic disparities in human papillomavirus vaccination initiation among U.S. women: a national population-based study. <i>Cancer Causes and Control</i> , 2018, 29, 927-936.	0.8	11

#	ARTICLE	IF	CITATIONS
109	Gynaecological disease in the developing world: a silent pandemic. <i>The Obstetrician and Gynaecologist</i> , 2018, 20, 237-244.	0.2	13
110	HPV vaccine implementation and monitoring in Latin America. <i>Salud Publica De Mexico</i> , 2018, 60, 683.	0.1	21
111	Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countriesâ€”Survey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1178-1184.	1.3	3
112	Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018, 23, 484-494.	0.3	9
113	Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. <i>Journal of Infectious Diseases</i> , 2018, 218, 95-108.	1.9	29
114	Exploring variation in human papillomavirus vaccination uptake in Switzerland: a multilevel spatial analysis of a national vaccination coverage survey. <i>BMJ Open</i> , 2018, 8, e021006.	0.8	25
115	Human papillomavirus (HPV) vaccination and factors related to intention to obtain the vaccine among young college women in Thailand. <i>Journal of Health Research</i> , 2018, 32, 142-151.	0.4	14
116	HPV single-dose vaccination: Impact potential, evidence base and further evaluation. <i>Vaccine</i> , 2018, 36, 4759-4760.	1.7	18
117	Impact of operational factors on HPV positivity rates in an HPVâ€”based screening study in Colombia. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 44-51.	1.0	1
118	HPV vaccination and the effects on rates of HPV-related cancers. <i>Current Problems in Cancer</i> , 2018, 42, 493-506.	1.0	62
119	Acting on non-communicable diseases in low- and middle-income tropical countries. <i>Nature</i> , 2018, 559, 507-516.	13.7	155
120	Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers?. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 468-483.	1.0	17
121	The Relationship of Health Beliefs with Information Sources and HPV Vaccine Acceptance among Young Adults in Korea. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 673.	1.2	21
122	Factors Associated with HPV Vaccine Refusal among Young Adult Women after Ten Years of Vaccine Implementation. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 770.	1.2	36
123	Knowledge, attitudes, and practices regarding cervical cancer and screening among women visiting primary health care Centres in Bahrain. <i>BMC Public Health</i> , 2018, 18, 128.	1.2	52
124	Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance. <i>MSphere</i> , 2018, 3, .	1.3	8
125	Accelerate progressâ€”sexual and reproductive health and rights for all: report of the Guttmacherâ€”Lancet Commission. <i>Lancet</i> , The, 2018, 391, 2642-2692.	6.3	610
126	Making <sc>HPV</sc> vaccination available to girls everywhere. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 267-276.	1.0	21



#	ARTICLE	IF	CITATIONS
127	Alkyl-imino sugars inhibit the pro-oncogenic ion channel function of human papillomavirus (HPV) E5. <i>Antiviral Research</i> , 2018, 158, 113-121.	1.9	26
128	Global Inequities in Precision Medicine and Molecular Cancer Research. <i>Frontiers in Oncology</i> , 2018, 8, 346.	1.3	44
129	Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact. <i>Vaccine</i> , 2018, 36, 4800-4805.	1.7	10
130	Pricing of HPV vaccines in European tender-based settings. <i>European Journal of Health Economics</i> , 2019, 20, 271-280.	1.4	18
131	Views of parents regarding human papillomavirus vaccination: A systematic review and meta-ethnographic synthesis of qualitative literature. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 331-337.	1.5	32
132	Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. <i>Vaccine</i> , 2019, 37, 3617-3624.	1.7	34
134	Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology. <i>Cancer Cytopathology</i> , 2019, 127, 567-577.	1.4	16
135	Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique. <i>BMC Public Health</i> , 2019, 19, 1031.	1.2	9
136	Recent Advances in Human Papillomavirus Infection and Management. , 0, , .		0
137	Advances in technologies for cervical cancer detection in low-resource settings. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 695-714.	1.5	25
138	Human papillomavirus vaccine disease impact beyond expectations. <i>Current Opinion in Virology</i> , 2019, 39, 16-22.	2.6	38
140	<p></p>Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1951-1967.	1.1	47
141	Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100177.	4.5	78
142	Cancers in Vietnam – Burden and Control Efforts: A Narrative Scoping Review. <i>Cancer Control</i> , 2019, 26, 107327481986380.	0.7	68
143	Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch, in rhesus macaques: An exploratory, pre-clinical feasibility assessment. <i>Vaccine: X</i> , 2019, 2, 100030.	0.9	19
144	Immunization Campaigns and Strategies against Human Papillomavirus in Italy: The Results of a Survey to Regional and Local Health Units Representatives. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	21
145	An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. <i>PLoS ONE</i> , 2019, 14, e0223612.	1.1	13
146	Local Management of Anogenital Warts in Non-immunocompromised Adults: A Systematic Review and Meta-analyses of Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2019, 9, 761-774.	1.4	5

#	ARTICLE	IF	CITATIONS
147	Hopes for Prevention of Anal Cancer in Women. <i>Journal of Infectious Diseases</i> , 2019, 221, 1210-1212.	1.9	0
148	Critical evaluation of arguments opposing male circumcision: A systematic review. <i>Journal of Evidence-Based Medicine</i> , 2019, 12, 263-290.	0.7	40
149	Prevalence and incidence of genital warts and cervical Human Papillomavirus infections in Nigerian women. <i>BMC Infectious Diseases</i> , 2019, 19, 27.	1.3	20
150	Facilitators and barriers of human papillomavirus vaccine uptake in young females 18â€“26 years old in Singapore: A qualitative study. <i>Vaccine</i> , 2019, 37, 6030-6038.	1.7	5
151	External Radiation and Brachytherapy Resource Deficit for Cervical Cancer in India: Call to Action for Treatment of All. <i>Journal of Global Oncology</i> , 2019, 5, 1-5.	0.5	11
152	Social and cultural construction processes involved in HPV vaccine hesitancy among Chinese women: a qualitative study. <i>International Journal for Equity in Health</i> , 2019, 18, 147.	1.5	26
153	Dynamic factors affecting HPV-attributable fraction for head and neck cancers. <i>Current Opinion in Virology</i> , 2019, 39, 33-40.	2.6	21
154	Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014â€“2017. <i>Vaccine</i> , 2019, 37, 6907-6914.	1.7	18
155	Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1317-1326.	1.2	11
156	Diversity of human papillomavirus typing among women population living in rural and remote areas of Brazilian territory. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100186.	4.5	5
157	Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 294.e17-294.e25.	0.8	5
158	Barriers and enablers to adolescent self-consent for vaccination: A mixed-methods evidence synthesis. <i>Vaccine</i> , 2019, 37, 417-429.	1.7	16
159	Eradication of human papillomavirus and elimination of HPV-related diseases â€“ scientific basis for global public health policies. <i>Expert Review of Vaccines</i> , 2019, 18, 153-160.	2.0	41
160	(At Least) Once in Her Lifetime: Global Cervical Cancer Prevention. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 107-123.	0.7	12
161	How Health Care Providers Can Use Digital Health Technologies to Inform Human Papillomavirus (HPV) Decision Making and Promote the HPV Vaccine Uptake Among Adolescents and Young Adults. <i>BioResearch Open Access</i> , 2019, 8, 84-93.	2.6	10
162	Global Collaborations for Cervical Cancer: Can the Eastâ€“West Alliance Facilitate Treatment for all?. <i>Clinical Oncology</i> , 2019, 31, 529-538.	0.6	9
163	HPV vaccines can be the hallmark of cancer prevention. <i>Lancet, The</i> , 2019, 394, 450-451.	6.3	10
164	Towards the global elimination of cervical cancer. <i>Papillomavirus Research (Amsterdam,)</i> Tj ETQq1 1 0.784314 rgBT <sub>1</sub> /Overlock 10 Tf 506	4.5	122

#	ARTICLE	IF	CITATIONS
165	Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States. <i>PLoS ONE</i> , 2019, 14, e0214151.	1.1	48
166	Understanding the use of digital technology to promote human papillomavirus vaccination – A RE-AIM framework approach. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1549-1561.	1.4	16
167	Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact. <i>Lancet Oncology</i> , The, 2019, 20, 915-923.	5.1	45
169	Modelling the impact of a <i>Schistosoma mansoni</i> vaccine and mass drug administration to achieve morbidity control and transmission elimination. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007349.	1.3	28
170	Distribution of cervical lesions in young and older women. <i>Diagnostic Cytopathology</i> , 2019, 47, 659-664.	0.5	5
171	PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2188.	1.8	71
172	Screening for Human Papillomavirus in a Low- and Middle-Income Country. <i>Journal of Global Oncology</i> , 2019, 5, JGO.18.00233.	0.5	6
173	Re-thinking breast and cervical cancer preventive campaigns in developing countries: the case for interventions at high schools. <i>BMC Public Health</i> , 2019, 19, 503.	1.2	16
174	What is needed now for successful scale-up of screening?. <i>Papillomavirus Research (Amsterdam,)</i> Tj ETQq0 0 0 rgBT /Overlock, 10 Tf 50 4	4.5	27
175	hrHPV prevalence and type distribution in rural Zimbabwe: A community-based self-collection study using near-point-of-care GeneXpert HPV testing. <i>International Journal of Infectious Diseases</i> , 2019, 82, 21-29.	1.5	16
176	Gender-neutral HPV vaccination in Africa. <i>The Lancet Global Health</i> , 2019, 7, e563.	2.9	1
177	<scp>HPV</scp>-vaccination and cancer cervical screening in 53 <scp>WHO</scp> European Countries: An update on prevention programs according to income level. <i>Cancer Medicine</i> , 2019, 8, 2524-2534.	1.3	32
178	Short Message Service Reminders to Parents for Increasing Adolescent Human Papillomavirus Vaccination Rates in a Secondary School Vaccine Program: A Randomized Control Trial. <i>Journal of Adolescent Health</i> , 2019, 65, 116-123.	1.2	29
179	Knowledge about HPV and vaccination among young adult men and women: Results of a national survey. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 7, 123-128.	4.5	37
180	Liquid biopsy of HPV DNA in cervical cancer. <i>Journal of Clinical Virology</i> , 2019, 114, 32-36.	1.6	49
181	HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: Results from the baseline phase of the Onclarity trial. <i>Gynecologic Oncology</i> , 2019, 153, 259-265.	0.6	15
182	HPV Vaccine: Updates and Highlights. <i>Acta Cytologica</i> , 2019, 63, 159-168.	0.7	53
183	Social Determinants of Human Papillomavirus Vaccine Uptake: An Assessment of Publicly Available Data. <i>Public Health Reports</i> , 2019, 134, 264-273.	1.3	8

#	ARTICLE	IF	CITATIONS
184	Global Disparities: Can the World Afford Cancer?. , 2019, , 79-94.		2
185	Opportunities to improve immune-based prevention of HPV-associated cancers. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 150-153.	4.5	13
186	Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006â€“2014: The impact of human papillomavirus vaccination. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 141-149.	4.5	9
187	A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine. Scientific Reports, 2019, 9, 5260.	1.6	45
188	Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine, 2019, 37, 2455-2462.	1.7	26
189	Persuasive messaging for human papillomavirus vaccination by adolescent providers in a five-country multi-site study. International Journal of Gynecological Cancer, 2019, 29, 250-256.	1.2	3
190	Prevalence and genotype distribution of human papillomavirus infection among women: A population-based study in Dali Bai Autonomous Prefecture, Yunnan Province, China. Journal of Medical Virology, 2019, 91, 1553-1561.	2.5	6
191	The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5â€“years of follow-up. Gynecologic Oncology, 2019, 153, 521-529.	0.6	43
192	Current knowledge of and attitudes toward human papillomavirus-related disease prevention among Japanese: A large-scale questionnaire study. Journal of Obstetrics and Gynaecology Research, 2019, 45, 994-1005.	0.6	16
193	One drug to treat them all: ethical implications of the MORDOR trial of mass antibiotic administration to reduce child mortality. Journal of Global Health, 2019, 9, 010305.	1.2	9
194	Using the precaution adoption process model to clarify human papillomavirus vaccine hesitancy in canadian parents of girls and parents of boys. Human Vaccines and Immunotherapeutics, 2019, 15, 1803-1814.	1.4	23
195	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020â€“99: a modelling study. Lancet Oncology, The, 2019, 20, 394-407.	5.1	279
196	A systematic literature review to examine the potential for social media to impact HPV vaccine uptake and awareness, knowledge, and attitudes about HPV and HPV vaccination. Human Vaccines and Immunotherapeutics, 2019, 15, 1465-1475.	1.4	136
197	Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling. MBio, 2019, 10, .	1.8	32
198	Factors that influence acceptance of human papillomavirus (HPV) vaccination for adolescents: a qualitative evidence synthesis. The Cochrane Library, 0, , .	1.5	7
199	Incidence and mortality due to cervical cancer in 4 south European countries. Porto Biomedical Journal, 2019, 4, e26.	0.4	2
200	The type-reproduction number of sexually transmitted infections through heterosexual and vertical transmission. Scientific Reports, 2019, 9, 17408.	1.6	6
201	Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins. Cell Death and Disease, 2019, 10, 876.	2.7	36

#	ARTICLE	IF	CITATIONS
202	Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirusâ€“16/18 Vaccine in Four- to Six-year-old Girls. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1061-1067.	1.1	11
203	&lt;p&gt;Non-Adherence To Childhood HPV Vaccination Is Associated With Non-Participation In Cervical Cancer Screening â€“ A Nationwide Danish Register-Based Cohort Study&lt;p&gt;. <i>Clinical Epidemiology</i> , 2019, Volume 11, 969-980.	1.5	10
204	HPV vaccines: alternative dosage schedules. <i>Expert Review of Vaccines</i> , 2019, 18, 1309-1316.	2.0	8
205	Machine Learning Classification of Cervical Tissue Liquid Based Cytology Smear Images by Optomagnetic Imaging Spectroscopy. <i>Tehnicki Vjesnik</i> , 2019, 26, .	0.3	2
206	Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz486.	0.4	10
207	Knowledge, understanding, attitude, perception and views on HPV infection and vaccination among health care students and professionals in Malaysia. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 156-162.	1.4	6
208	Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. <i>Oncolmunology</i> , 2019, 8, e1524694.	2.1	8
209	â€“I also want to be vaccinated!â€™ â€“ adolescent boysâ€™ awareness and thoughts, perceived benefits, information sources, and intention to be vaccinated against Human papillomavirus (HPV). <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1794-1802.	1.4	18
210	Assessment of herd effects among women and heterosexual men after girlsâ€™only HPV16/18 vaccination in the Netherlands: A repeated crossâ€“sectional study. <i>International Journal of Cancer</i> , 2019, 144, 2718-2727.	2.3	13
211	An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 849-859.	2.0	19
212	HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1615-1627.	1.4	168
213	New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1-10.	0.4	41
214	Clinician offering is a key factor associated with HPV vaccine uptake among Mexican mothers in the USA and Mexico: a cross-sectional study. <i>International Journal of Public Health</i> , 2019, 64, 323-332.	1.0	10
215	The projected timeframe until cervical cancer elimination in Australia: a modelling study. <i>Lancet Public Health</i> , The, 2019, 4, e19-e27.	4.7	268
216	Effects of Multimedia Framed Messages on Human Papillomavirus Prevention Among Adolescents. <i>Western Journal of Nursing Research</i> , 2019, 41, 58-77.	0.6	10
217	Factors Affecting Delivery of the HPV Vaccination: A Focus Group Study With NHS School-Aged Vaccination Teams in London. <i>Journal of School Nursing</i> , 2020, 36, 135-143.	0.9	7
218	Cervical cancer risk in women living with HIV across four continents: A multicohort study. <i>International Journal of Cancer</i> , 2020, 146, 601-609.	2.3	37
219	Current Status and Future Perspectives of Molecular Prevention Strategies for Cervical Cancers. <i>Indian Journal of Surgical Oncology</i> , 2020, 11, 752-761.	0.3	2

#	ARTICLE	IF	CITATIONS
220	Human papillomavirus as an independent risk factor of invasive cervical and endometrial carcinomas in Jordan. <i>Journal of Infection and Public Health</i> , 2020, 13, 613-618.	1.9	12
221	Gender-neutral HPV vaccination in developing countries“is it time?. <i>Public Health</i> , 2020, 179, 66-67.	1.4	0
222	School-based delivery of routinely recommended vaccines and opportunities to check vaccination status at school, a global summary, 2008“2017. <i>Vaccine</i> , 2020, 38, 680-689.	1.7	18
223	Uptake of the HPV vaccine among people with and without HIV, cisgender and transgender women and men who have sex with men and with women at two sexual health clinics in Mexico City. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 981-990.	1.4	9
224	Adolescent HPV vaccination: empowerment, equity and ethics. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1835-1840.	1.4	12
225	A global epidemic increase of an HPV“induced tonsil and tongue base cancer “ potential benefit from a pan“gender use of HPV vaccine. <i>Journal of Internal Medicine</i> , 2020, 287, 134-152.	2.7	71
226	Resilience of HPV vaccine uptake in Denmark: Decline and recovery. <i>Vaccine</i> , 2020, 38, 1842-1848.	1.7	49
227	Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. <i>Cancer Letters</i> , 2020, 471, 88-102.	3.2	229
228	Clinical Trials of Human Papillomavirus Vaccines. , 2020, , 299-325.		1
229	Updates in Cervical Cancer Treatment. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 3-11.	0.6	34
230	Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. <i>The Lancet Global Health</i> , 2020, 8, e191-e203.	2.9	2,111
231	The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. <i>Preventive Medicine</i> , 2020, 131, 105931.	1.6	9
232	Human Papillomavirus Infections, Cervical Cancer and MicroRNAs: An Overview and Implications for Public Health. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2020, 9, 174-186.	0.6	9
233	Barriers to vaccination in Latin America: A systematic literature review. <i>Vaccine</i> , 2020, 38, 470-481.	1.7	106
234	Strengthening national teams of experts to support HPV vaccine introduction in Eastern Mediterranean countries: Lessons learnt and recommendations from an international workshop. <i>Vaccine</i> , 2020, 38, 1114-1119.	1.7	3
235	Systematic Review and Meta-analysis of Postlicensure Observational Studies on Human Papillomavirus Vaccination and Autoimmune and Other Rare Adverse Events. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 287-293.	1.1	12
236	A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. <i>European Journal of Cancer Prevention</i> , 2020, 29, 157-164.	0.6	9
237	Lifetime Prevalence of Cervical Cancer Screening in 55 Low- and Middle-Income Countries. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1532.	3.8	86



#	ARTICLE	IF	CITATIONS
238	Meeting the Global Need for Radiation Therapy in Cervical Cancer—An Overview. <i>Seminars in Radiation Oncology</i> , 2020, 30, 348-354.	1.0	15
239	Human Papillomavirus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism of Self-Clearance. , 0, , .		3
240	Comparison of immunization systems in Japan and the United States — What can be learned?. <i>Vaccine</i> , 2020, 38, 7401-7408.	1.7	8
241	Burden of non-communicable diseases from infectious causes in 2017: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e1489-e1498.	2.9	61
242	The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature. <i>Current Treatment Options in Oncology</i> , 2020, 21, 95.	1.3	15
243	Human papillomavirus (HPV) vaccine status and knowledge of students at a university in rural Thailand. <i>Heliyon</i> , 2020, 6, e04625.	1.4	14
244	Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: a systematic review. <i>Health Policy and Planning</i> , 2020, 35, 701-717.	1.0	27
245	Chinese Vaccine Providers—Perspectives on the HPV Vaccine. <i>Global Pediatric Health</i> , 2020, 7, 2333794X2096759.	0.3	3
246	How to reduce the impact of cervical cancer worldwide: Gaps and priority areas identified through the essential cancer and primary care packages: An analysis of effective interventions. <i>Cancer</i> , 2020, 126, 4697-4705.	2.0	6
247	Human Papillomavirus Vaccines: An Updated Review. <i>Vaccines</i> , 2020, 8, 391.	2.1	130
248	Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine. <i>Frontiers in Immunology</i> , 2020, 11, 1434.	2.2	15
249	The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. <i>Lancet Oncology</i> , The, 2020, 21, 1089-1098.	5.1	32
250	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade—specific epigenome and transcriptome landscapes. <i>Nature Genetics</i> , 2020, 52, 800-810.	9.4	40
251	Universal cervical cancer control through a right to health lens: refocusing national policy and programmes on underserved women. <i>BMC International Health and Human Rights</i> , 2020, 20, 21.	2.5	9
252	The potential impact of human visceral leishmaniasis vaccines on population incidence. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008468.	1.3	12
253	Long-term persistence of immune response to the AS04—adjuvanted HPV—16/18 vaccine in Chinese girls aged 9—17 years: Results from an 8—year follow-up phase III open-label study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 392-399.	0.7	2
254	Letter to the Editor Regarding —A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc® Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts—™. <i>Dermatology and Therapy</i> , 2020, 10, 1435-1437.	1.4	0
255	Immunogenicity of Alternative Dosing Schedules for HPV Vaccines among Adolescent Girls and Young Women: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2020, 8, 618.	2.1	4

#	ARTICLE	IF	CITATIONS
256	The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. <i>Lancet Public Health</i> , The, 2020, 5, e592-e603.	4.7	16
257	Effect of human papilloma virus vaccination on sexual behaviours among adolescent women in Rwanda: a regression discontinuity study. <i>Health Policy and Planning</i> , 2020, 35, 1021-1028.	1.0	1
258	Effects of a multidisciplinary team-led school-based human papillomavirus vaccination health-promotion programme on improving vaccine acceptance and uptake among female adolescents. <i>Medicine (United States)</i> , 2020, 99, e22072.	0.4	1
259	&lt;p&gt;Determinants of VIA Positivity Among Women Screened for Cervical Precancerous Lesion in Public Hospitals of Oromia Region, Ethiopia: Unmatched Case-Control Study&lt;/p&gt;. <i>International Journal of Women's Health</i> , 2020, Volume 12, 587-596.	1.1	3
260	Can a single dose of the human papilloma virus (HPV) vaccine prevent oropharyngeal cancer?. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e234-e236.	0.4	2
261	Bibliometric analysis of global scientific literature on vaccine hesitancy in peer-reviewed journals (1990â€“2019). <i>BMC Public Health</i> , 2020, 20, 1252.	1.2	41
262	The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018â€“2019). <i>Expert Review of Vaccines</i> , 2020, 19, 1073-1083.	2.0	27
263	Caught in the Crossfire: How Contradictory Information and Norms on Social Media Influence Young Womenâ€™s Intentions to Receive HPV Vaccination in the United States and China. <i>Frontiers in Psychology</i> , 2020, 11, 548365.	1.1	15
264	Loss, Doubt, and Betrayal: Strands of Vaccination Skepticism on Three Facebook Pages Involved in the Controversy Over Human Papillomavirus (HPV) Vaccination. <i>Frontiers in Communication</i> , 2020, 5, .	0.6	2
265	Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs). <i>Vaccines</i> , 2020, 8, 740.	2.1	18
266	Modeling for Predictors of Knowledge Score on Etiology and Prevention Strategies for Cervical Cancer Among Women of Reproductive Age in Ibadan. <i>JCO Global Oncology</i> , 2020, 6, 892-903.	0.8	2
267	Increasing HPV Vaccination Uptake among Adolescents: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7997.	1.2	31
268	Prioritisation of the human papillomavirus vaccine in a time of constrained supply. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 349-351.	2.7	6
269	A comparative analysis of cervical cancer prevention between Nigeria and Nordic countries that have experienced a decline in cervical cancer incidence. <i>International Health</i> , 2021, 13, 307-317.	0.8	5
270	Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study. <i>In Vivo</i> , 2020, 34, 1445-1449.	0.6	15
271	Burden and Prevention of HPV. Knowledge, Practices and Attitude Assessment Among Pre-Adolescents and their Parents in Italy. <i>Current Pharmaceutical Design</i> , 2020, 26, 326-342.	0.9	16
272	Policy implications of the potential use of a novel vaccine to prevent infection with <i>Schistosoma mansoni</i> with or without mass drug administration. <i>Vaccine</i> , 2020, 38, 4379-4386.	1.7	12
273	Longâ€term followâ€up of human papillomavirus type replacement among young pregnant Finnish females before and after a communityâ€randomised <scp>HPV</scp> vaccination trial with moderate coverage. <i>International Journal of Cancer</i> , 2020, 147, 3511-3522.	2.3	13



#	ARTICLE	IF	CITATIONS
274	Human papillomavirus: The other invisible enemy. <i>Gynecologic Oncology</i> , 2020, 158, 254-255.	0.6	0
275	Strengthening health care worker engagement with early adolescence in low- and middle-income countries: an overdue area for action. <i>International Journal of Adolescent Medicine and Health</i> , 2022, 34, .	0.6	4
276	Sex Disparities in the Global Burden of Surgical Disease. <i>World Journal of Surgery</i> , 2020, 44, 2139-2143.	0.8	3
277	Public-private knowledge transfer and access to medicines: a systematic review and qualitative study of perceptions and roles of scientists involved in HPV vaccine research. <i>Globalization and Health</i> , 2020, 16, 22.	2.4	5
278	Cervical cancer burden in Latin America and the Caribbean: Where are we?. <i>International Journal of Cancer</i> , 2020, 147, 1638-1648.	2.3	41
279	Antiretroviral Therapy and Detection of High-grade Cervical Intraepithelial Neoplasia (CIN2+) at Post-CIN Management Follow-up Among Women Living With Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, e540-e548.	2.9	5
280	Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries – The ADVANCE project. <i>Vaccine</i> , 2020, 38, 3243-3254.	1.7	10
281	IPVS statement on –Temporary HPV vaccine shortage: Implications globally to achieve equity–. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 9, 100195.	4.5	19
282	HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). <i>Vaccines</i> , 2020, 8, 354.	2.1	21
283	Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 274-280.	157.7	93
284	Human papillomavirus genotyping on Reunion Island: A cross-sectional study of stored tissue samples. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 294-299.	0.5	6
285	Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 532-557.	1.8	67
286	Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo. <i>International Immunopharmacology</i> , 2020, 86, 106718.	1.7	18
287	Local Management of Anogenital Warts in Non-Immunocompromised Adults: A Network Meta-Analysis of Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 249-262.	1.4	11
288	More evidence suggesting that 1-dose human papillomavirus vaccination may be effective. <i>Cancer</i> , 2020, 126, 1602-1604.	2.0	2
289	Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1038-1046.	3.0	89
290	Improving vaccination uptake among adolescents. <i>The Cochrane Library</i> , 2020, 2020, CD011895.	1.5	48
291	Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. <i>Lancet HIV</i> , 2020, 7, e262-e278.	2.1	46

#	ARTICLE	IF	CITATIONS
292	Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France. PLoS ONE, 2020, 15, e0228660.	1.1	7
293	Global burden of cancer attributable to infections: the critical role of implementation science. The Lancet Global Health, 2020, 8, e153-e154.	2.9	15
294	Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?. PLoS Medicine, 2020, 17, e1003035.	3.9	36
295	Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan. Cancer Science, 2020, 111, 2156-2162.	1.7	43
296	Vaccination coverage rates and predictors of HPV vaccination among eligible and non-eligible female adolescents at the Brazilian HPV vaccination public program. BMC Public Health, 2020, 20, 458.	1.2	15
297	Triage options to manage high-risk human papillomavirus positive women: A population-based cross-sectional study from rural China. International Journal of Cancer, 2020, 147, 2053-2064.	2.3	17
298	The Impact of Narrative Strategy on Promoting HPV Vaccination among College Students in Korea: The Role of Anticipated Regret. Vaccines, 2020, 8, 176.	2.1	11
299	The early detection of cervical cancer. The current and changing landscape of cervical disease detection. Cytopathology, 2020, 31, 258-270.	0.4	19
300	The Role of Vaccination and Screening in Limiting the Worldwide Disease Burden of Preventable Female Cancers: A Review. Women, 2021, 1, 16-28.	0.5	4
301	Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review. Preventive Medicine, 2021, 143, 106323.	1.6	13
302	Vaccination against HPV: boosting coverage and tackling misinformation. Molecular Oncology, 2021, 15, 770-778.	2.1	21
303	Uncertainty and sensitivity of the sexual behavior changes to the current human papillomavirus vaccination campaign in Spain. Mathematical Methods in the Applied Sciences, 2021, 44, 7845-7857.	1.2	9
304	Human papillomavirus vaccination uptake: a longitudinal study showing ethnic differences in the influence of the intention-to-vaccinate among parent-daughter dyads. Human Vaccines and Immunotherapeutics, 2021, 17, 990-999.	1.4	3
305	Vaccine attitudes among young adults in Asia: a systematic review. Human Vaccines and Immunotherapeutics, 2021, 17, 1142-1155.	1.4	1
306	Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers. Frontiers in Immunology, 2020, 11, 586796.	2.2	15
307	Cervical Cancer Screening. , 2021, , 151-159.		0
308	An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model. Vaccines, 2021, 9, 149.	2.1	13
309	A systematic review of the barriers to implementing human papillomavirus vaccination programs in low-and middle-income countries in the Asia-Pacific. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 530-545.	0.7	12

#	ARTICLE	IF	CITATIONS
310	Determinants of dentists's™ readiness to assess HPV risk and recommend immunization: A transtheoretical model of change-based cross-sectional study of Ontario dentists. PLoS ONE, 2021, 16, e0247043.	1.1	5
311	Downregulation of LncRNA DARS-AS1 Inhibits the Tumorigenesis of Cervical Cancer via Inhibition of IGF2BP3. OncoTargets and Therapy, 2021, Volume 14, 1331-1340.	1.0	10
312	A high-content AlphaScreen,¢ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas. Oncotarget, 2021, 12, 549-561.	0.8	6
313	Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. Preventive Medicine, 2021, 144, 106321.	1.6	12
314	Can mHealth interventions contribute to increased HPV vaccination uptake? A systematic review. Preventive Medicine Reports, 2021, 21, 101289.	0.8	9
315	Review of Chinese young adults' human papillomavirus knowledge, attitudes, and vaccine acceptability. Public Health Nursing, 2021, 38, 701-714.	0.7	1
316	HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010â€“2019. Preventive Medicine, 2021, 144, 106399.	1.6	329
317	The prevalence and distribution of human papillomavirus among 10,867 Chinese Han women. Infectious Agents and Cancer, 2021, 16, 21.	1.2	8
318	Oral health care professionals recommending and administering the HPV vaccine: Understanding the strengths and assessing the barriers. PLoS ONE, 2021, 16, e0248047.	1.1	14
319	The World Cancer Declaration: time to consolidate wins and work towards 2025. Lancet Oncology, The, 2021, 22, 296-298.	5.1	7
320	Barriers to and Facilitators of Human Papillomavirus Vaccination Among People Aged 9 to 26 Years: A Systematic Review. Sexually Transmitted Diseases, 2021, 48, e255-e262.	0.8	29
321	The challenges of defining sample adequacy in an era of HPV based cervical screening. Journal of Clinical Virology, 2021, 137, 104756.	1.6	8
322	Do Health-Seeking Populations Know the Link Between Human Papillomavirus and Oropharyngeal Cancer? A Cross-Sectional Study in a Nigerian Population. International Quarterly of Community Health Education, 2021, , 0272684X2110066.	0.4	1
323	Cytological physiognomies and genotype distribution of human papillomaviruses among HPV/HIV co-infected and HPV mono-infected women. African Health Sciences, 2021, 21, 254-62.	0.3	0
324	Human papillomavirus vaccination uptake in low-and middle-income countries: a meta-analysis. EclinicalMedicine, 2021, 34, 100836.	3.2	44
325	T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates. Frontiers in Immunology, 2021, 12, 624230.	2.2	3
326	Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium. Frontiers in Pharmacology, 2021, 12, 628434.	1.6	5
327	Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. American Journal of Preventive Medicine, 2021, 60, 478-487.	1.6	13

#	ARTICLE	IF	CITATIONS
328	Knowledge on cervical cancer screening and vaccination among females at Oyibi Community. <i>BMC Women's Health</i> , 2021, 21, 148.	0.8	5
329	Human Papillomavirus, Related Diseases, and Vaccination: Knowledge and Awareness Among Health Care Students and Professionals in Nepal. <i>Journal of Cancer Education</i> , 2022, 37, 1727-1735.	0.6	3
330	PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6. <i>Molecules</i> , 2021, 26, 3004.	1.7	6
331	Pediatric and adolescent gynecology through a global lens. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 156, 189-196.	1.0	4
332	Soluble production of a full-length human papillomavirus type 16 L1 protein by <i>Escherichia coli</i> . <i>Revista Bionatura</i> , 2021, 6, 1684-1691.	0.1	0
333	Health Care Provider Perceptions of Facilitators and Barriers to Human Papillomavirus Vaccination Delivery in Five Countries. <i>Sexually Transmitted Diseases</i> , 2021, 48, 557-564.	0.8	0
334	Role of IQGAP1 in Papillomavirus-Associated Head and Neck Tumorigenesis. <i>Cancers</i> , 2021, 13, 2276.	1.7	8
335	Vaccines for immunoprevention of cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	39
336	Male Circumcision Reduces Penile HPV Incidence and Persistence: A Randomized Controlled Trial in Kenya. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1139-1148.	1.1	12
337	Contemporary hormonal contraception and cervical cancer in women of reproductive age. <i>International Journal of Cancer</i> , 2021, 149, 769-777.	2.3	15
338	Human Papillomavirus Vaccine to End Oropharyngeal Cancer. A Systematic Review and Meta-Analysis. <i>Sexually Transmitted Diseases</i> , 2021, 48, 700-707.	0.8	21
339	Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	8
340	HPV vaccine: Expanding indications and global disparity. <i>Vaccine</i> , 2021, 39, 3787-3789.	1.7	1
341	Human papillomavirus vaccination coverage and knowledge, perceptions and influencing factors among university students in Guangzhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3603-3612.	1.4	18
342	Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003588.	3.9	8
343	Success of community approach to HPV vaccination in school-based and non-school-based settings in Haiti. <i>PLoS ONE</i> , 2021, 16, e0252310.	1.1	4
344	Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 663-672.	12.5	319
345	High human papillomavirus prevalence among females attending high school in the Eastern Cape Province of South Africa. <i>PLoS ONE</i> , 2021, 16, e0253074.	1.1	15

#	ARTICLE	IF	CITATIONS
346	Cervical Cancer Prevention in Low- and Middle-Income Countries. <i>Clinical Obstetrics and Gynecology</i> , 2021, 64, 501-518.	0.6	3
347	Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals. <i>Contemporary Clinical Trials</i> , 2021, 105, 106403.	0.8	2
348	A systematic review and meta-analysis of the prevalence of human papillomavirus infection in Indigenous populations – A Global Picture. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 843-854.	1.4	7
349	Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico. <i>Vaccine</i> , 2021, 39, 3388-3396.	1.7	3
350	Preference and willingness to pay of female college students for human papillomavirus vaccination in Zhejiang Province, China: A discrete choice experiment. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3595-3602.	1.4	3
351	Factors influencing cervical cancer screening practice among female health workers in Nigeria: A systematic review. <i>Cancer Reports</i> , 2022, 5, e1514.	0.6	11
352	The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana. <i>Vaccine</i> , 2022, 40, A85-A93.	1.7	12
353	Sociodemographic Correlates of Human Papillomavirus Vaccine Uptake: Opportunistic and Catch-Up Vaccination in Norway. <i>Cancers</i> , 2021, 13, 3483.	1.7	9
354	Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus. <i>Environmental Science and Pollution Research</i> , 2021, 28, 47752-47772.	2.7	7
355	Missed Opportunities for Human Papillomavirus Vaccination by Parental Nativity, Minnesota, 2015-2018. <i>Public Health Reports</i> , 2022, 137, 867-877.	1.3	1
357	Knowledge and Attitude towards Cervical Cancer and Human Papillomavirus among Pharmacists in Japan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2259-2265.	0.5	1
358	A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities. <i>Frontiers in Public Health</i> , 2021, 9, 670032.	1.3	25
359	Construct a novel 5 hypoxia genes signature for cervical cancer. <i>Cancer Cell International</i> , 2021, 21, 345.	1.8	16
360	Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. <i>Cancer</i> , 2021, 127, 4030-4039.	2.0	70
361	Environmental factors affecting mothers' decision-making about the HPV vaccination for their daughters. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4412-4417.	1.4	5
362	Barriers towards HPV Vaccinations for Boys and Young Men: A Narrative Review. <i>Viruses</i> , 2021, 13, 1644.	1.5	31
363	Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland. <i>Cancer Medicine</i> , 2021, 10, 7759-7771.	1.3	2
364	Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4470-4486.	1.4	27

#	ARTICLE	IF	CITATIONS
365	The role of maturity in adolescent decision-making around HPV vaccination in France. <i>Vaccine</i> , 2021, 39, 5741-5747.	1.7	10
366	Qualitative assessment of attitudes toward cervical cancer (CC) screening and HPV self-sampling among African American (AA) and Sub Saharan African Immigrant (SAI) women. <i>Ethnicity and Health</i> , 2022, 27, 1769-1786.	1.5	1
367	Comparison of Different HPV-based Strategies and Cytology in Routine Cervical Cancer Screening Programme in China: A Population-based Study. <i>Cancer Prevention Research</i> , 2022, 15, 45-54.	0.7	5
368	Factors Influencing the Popularity of a Health-Related Answer on a Chinese Question-and-Answer Website: Case Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e29885.	2.1	7
369	The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3562-3576.	1.4	5
370	Projected Association of Human Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US, 2020-2045. <i>JAMA Oncology</i> , 2021, 7, e212907.	3.4	57
371	Pre-vaccination vulnerability and suspected adverse events following HPV vaccination. A case-control study nested in the Danish national birth cohort. <i>Vaccine</i> , 2021, 39, 6364-6369.	1.7	1
372	Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System. <i>Drugs - Real World Outcomes</i> , 2022, 9, 79-90.	0.7	6
373	High-risk HPV genotypes in Zimbabwean women with cervical cancer: Comparative analyses between HIV-negative and HIV-positive women. <i>PLoS ONE</i> , 2021, 16, e0257324.	1.1	15
374	Human papillomavirus vaccinations matter!. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1341-1342.	4.6	2
375	Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106560.	0.8	3
376	Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania. <i>Tumour Virus Research</i> , 2021, 12, 200217.	1.5	0
377	Knowledge and awareness of nursing students regarding human papillomaviruses infection and vaccination. <i>Vojnosanitetski Pregled</i> , 2022, 79, 890-896.	0.1	0
378	Human Papillomavirus Vaccines. , 2021, , 147-157.		0
379	Aluminium adjuvants used in vaccines. <i>The Cochrane Library</i> , 0, , .	1.5	11
380	Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer. <i>Recent Results in Cancer Research</i> , 2021, 217, 157-195.	1.8	20
381	HPV vaccination strategies targeting hard-to-reach populations: Out-of-school girls in LMICs. <i>Vaccine</i> , 2018, 36, 191-193.	1.7	16
382	Acceptability of human papillomavirus vaccination among medical students in Mangalore, India. <i>Vaccine</i> , 2019, 37, 1174-1181.	1.7	14



#	ARTICLE	IF	CITATIONS
383	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 591-603.	6.3	321
384	Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies. <i>Journal of General Virology</i> , 2017, 98, 1755-1761.	1.3	12
385	Recent advances in understanding and preventing human papillomavirus-related disease. <i>F1000Research</i> , 2017, 6, 269.	0.8	7
386	Vaccination to prevent human papillomavirus infections: From promise to practice. <i>PLoS Medicine</i> , 2017, 14, e1002325.	3.9	40
387	HPV vaccine knowledge and acceptability among Peruvian men who have sex with men and transgender women: A pilot, qualitative study. <i>PLoS ONE</i> , 2017, 12, e0172964.	1.1	13
388	School nurses' attitudes towards and experiences of the Swedish school-based HPV vaccination programme – A repeated cross sectional study. <i>PLoS ONE</i> , 2017, 12, e0175883.	1.1	18
389	Catch-up HPV vaccination status of adolescents in relation to socioeconomic factors, individual beliefs and sexual behaviour. <i>PLoS ONE</i> , 2017, 12, e0187193.	1.1	24
390	Parents' knowledge, beliefs, and acceptance of the HPV vaccination in relation to their socio-demographics and religious beliefs: A cross-sectional study in Thailand. <i>PLoS ONE</i> , 2018, 13, e0193054.	1.1	52
391	Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 383-394.	0.7	4
392	Alternative HPV vaccination schedules in Latin America. <i>Salud Publica De Mexico</i> , 2018, 60, 693.	0.1	2
393	Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2017, 41, 1.	0.6	4
394	MODERN ASPECTS OF HUMAN PAPILOMAVIRUS VACCINATION. Safety and Risk of Pharmacotherapy, 2018, 6, 111-117.	0.1	1
395	Influence of Income on Cancer Incidence and Death among Patients in Aomori, Japan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3193-3202.	0.5	11
396	Knowledge of Human Papillomavirus (HPV) and Oropharyngeal Cancer and Acceptability of the HPV Vaccine among Dental Students. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3595-3603.	0.5	7
397	Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. <i>Emerging Infectious Diseases</i> , 2020, 27, 1-9.	2.0	21
398	Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution's Experience. <i>Vaccines</i> , 2020, 8, 45.	2.1	27
400	Prevention of Cervical Cancer. <i>Journal of Cancer Therapy</i> , 2018, 09, 79-88.	0.1	4
401	Awareness and uptake of human papilloma virus vaccines among female secondary school students in Benin City, Nigeria. <i>African Health Sciences</i> , 2020, 20, 45-50.	0.3	9

#	ARTICLE	IF	CITATIONS
402	Reducing Premature Mortality from Cardiovascular and Other Non-Communicable Diseases by One Third: Achieving Sustainable Development Goal Indicator 3.4.1. <i>Global Heart</i> , 2020, 15, 50.	0.9	31
403	HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg. <i>PeerJ</i> , 2020, 8, e8516.	0.9	1
404	Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. <i>Gynecologic Oncology</i> , 2021, 163, 583-592.	0.6	30
405	School-Level Variation in Coverage of Co-Administered dTpa and HPV Dose 1 in Three Australian States. <i>Vaccines</i> , 2021, 9, 1202.	2.1	4
406	Reduction in Vaccine HPV Type Infections in a Young Women Group (18â€“25 Years) Five Years after HPV Vaccine Introduction in Colombia. <i>Cancer Prevention Research</i> , 2022, 15, 55-66.	0.7	1
407	The dynamic interactome of microRNAs and the human papillomavirus in head and neck cancers. <i>Current Opinion in Virology</i> , 2021, 51, 87-95.	2.6	2
408	Human Papillomavirus Vaccines. , 2017, , 127-136.		0
411	Human papillomavirus infection and immunization strategies. <i>Infectio Ro</i> , 2018, 2, 17.	0.0	0
412	Strategies for Progress. , 2019, , 3-43.		0
413	Realities of alternative HPV vaccination schedules. <i>Salud Publica De Mexico</i> , 2018, 60, 617.	0.1	0
414	The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules. <i>Salud Publica De Mexico</i> , 2018, 60, 666.	0.1	2
415	Municipally sponsored human papillomavirus (HPV) vaccination of boys in Slovenia: the first 4 years. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2019, 28, .	0.1	2
416	The prevalence of hrHPV in a significant cohort of Romanian women. <i>Romanian Biotechnological Letters</i> , 2019, 24, 75-81.	0.5	0
418	Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned. <i>AIDS Reviews</i> , 2019, 21, 218-232.	0.5	6
419	Achievements and Prospects of Vaccination against Human Papillomavirus Infection and Associated Diseases. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2020, 19, 110-118.	0.2	1
421	Kesediaan Vaksinasi HPV pada Remaja Putri Ditinjau dari Faktor Orang Tua. <i>Jurnal Ners Dan Kebidanan (Journal of Ners and Midwifery)</i> , 2020, 7, 213-222.	0.0	0
422	Pharmacists' knowledge and attitudes about the HPV vaccine. <i>Zdravstvena Zastita</i> , 2020, 49, 39-46.	0.0	0
423	Cochrane corner: improving vaccination coverage among adolescents. <i>Pan African Medical Journal</i> , 2020, 37, 160.	0.3	1



#	ARTICLE	IF	CITATIONS
424	Influence of Gender and Undergraduate Course on the Knowledge about HPV and HPV Vaccine, and Vaccination Rate among Students of a Public University. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2020, 42, 096-105.	0.3	8
426	Achievements and Prospects of Vaccination against Human Papillomavirus Infection and Associated Diseases. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2020, 19, 110-118.	0.2	0
427	Ongoing challenges and future directions of human papillomavirus vaccination. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 141-150.	0.1	0
428	Human Papillomavirus (HPV) and the quadrivalent HPV Vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance. <i>PLoS ONE</i> , 2020, 15, e0241674.	1.1	14
429	Increased Burden of Concordant and Sequential Anogenital Human Papillomavirus Infections Among Asian Young Adult Women With Perinatally Acquired HIV Compared With HIV-Negative Peers. <i>Sexually Transmitted Diseases</i> , 2021, 48, 200-205.	0.8	0
430	Topical application of temperature-sensitive caerin 1.1 and 1.9 gel inhibits TC-1 tumor growth in mice. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 191-202.	0.0	7
431	Comparison of the costs of HPV testing through community health campaigns versus home-based testing in rural Western Kenya: a microcosting study. <i>BMJ Open</i> , 2020, 10, e033979.	0.8	1
432	Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators. <i>BMJ Open</i> , 2021, 11, e052016.	0.8	3
433	The State of Cervical Cancer Screening and HPV Vaccination in Africa: In the Advent of Advanced Health Care. <i>Journal of Biomedical Research &amp; Environmental Sciences</i> , 2021, 2, 985-998.	0.1	0
434	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. <i>Vaccine</i> , 2022, 40, 76-88.	1.7	15
435	HPV vaccine: uptake and understanding among global Indigenous communities – a qualitative systematic review. <i>BMC Public Health</i> , 2021, 21, 2062.	1.2	10
436	Preventing Cervical Cancer Globally: Are We Making Progress?. <i>Cancer Prevention Research</i> , 2021, 14, 1055-1060.	0.7	6
437	Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education. <i>Gynecologic Oncology</i> , 2022, 164, 675-690.	0.6	8
438	Cervix Uteri Cancer in Lebanon: Incidence, Temporal Trends, and Comparison to Countries From Different Regions in the World. <i>Cancer Control</i> , 2022, 29, 107327482110686.	0.7	0
439	Comparison of the costs of HPV testing through community health campaigns versus home-based testing in rural Western Kenya: a microcosting study. <i>BMJ Open</i> , 2020, 10, e033979.	0.8	1
440	The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies. <i>Viruses</i> , 2022, 14, 214.	1.5	14
441	Examining Clinical Practice Guidelines for Male Circumcision: A Systematic Review and Critical Appraisal Using AGREE II. <i>Journal of Pediatrics</i> , 2022, 244, 186-193.e6.	0.9	2
442	The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions. <i>Cancer Medicine</i> , 2022, 11, 1542-1552.	1.3	2

#	ARTICLE	IF	CITATIONS
443	Risk of Guillain-Barré syndrome after vaccination against human papillomavirus: a systematic review and meta-analysis, 1 January 2000 to 4 April 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	2
444	Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030. <i>BMC Public Health</i> , 2022, 22, 113.	1.2	7
445	“I trust them because my mum trusts them”: Exploring the role of trust in HPV vaccination decision-making among adolescent girls and their mothers in France. <i>Vaccine</i> , 2022, 40, 1090-1097.	1.7	10
446	Human papillomavirus infection and seroprevalence among female university students in Mexico. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	4
447	Incidence and mortality of cervical cancer in China in 2015. <i>Journal of the National Cancer Center</i> , 2022, 2, 70-77.	3.0	10
448	Mapping sociodemographic and geographical differences in human papillomavirus non-vaccination among young girls in Sweden. <i>Scandinavian Journal of Public Health</i> , 2023, 51, 288-295.	1.2	6
449	Immunotherapeutic approaches for HPV-caused cervical cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, 129, 51-90.	1.0	2
450	High prevalence of cervical cancer in the Marajó archipelago: an active search study. <i>Obstetrics &amp; Gynecology International Journal</i> , 2022, 13, 26-30.	0.0	0
451	Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1101.	1.0	9
452	Cervical Intraepithelial Neoplasia Grade 3 in a HPV-Vaccinated Patient: A Case Report. <i>Medicina (Lithuania)</i> , 2022, 58, 339.	0.8	4
453	HPV vaccine introduction and implementation in Low- and Middle-Income Countries. <i>Vaccine</i> , 2022, 40, A1.	1.7	1
454	Impact of the COVID-19 Pandemic on Human Papillomavirus Vaccination in Brazil. <i>International Journal of Public Health</i> , 2022, 67, 1604224.	1.0	11
455	High human papillomavirus (HPV)-35 prevalence among South African women with cervical intraepithelial neoplasia warrants attention. <i>PLoS ONE</i> , 2022, 17, e0264498.	1.1	11
456	Social media-assisted interventions on human papillomavirus and vaccination-related knowledge, intention and behavior: a scoping review. <i>Health Education Research</i> , 2022, 37, 104-132.	1.0	4
457	Development and Validation of a Raman Spectroscopic Classification Model for Cervical Intraepithelial Neoplasia (CIN). <i>Cancers</i> , 2022, 14, 1836.	1.7	6
458	The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2022, , 1.	0.8	3
459	Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators. <i>BMJ Open</i> , 2021, 11, e052016.	0.8	46
460	Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis. <i>PLoS ONE</i> , 2021, 16, e0260808.	1.1	16

#	ARTICLE	IF	CITATIONS
461	Acculturation Strategies and Pap Screening Uptake among Sub-Saharan African Immigrants (SAls). <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13204.	1.2	3
462	Study protocol for a two-site clinical trial to validate a smartphone-based artificial intelligence classifier identifying cervical precancer and cancer in HPV-positive women in Cameroon. <i>PLoS ONE</i> , 2021, 16, e0260776.	1.1	2
463	Global, regional, and national burden of cervical cancer for 195 countries and territories, 2007–2017: findings from the Global Burden of Disease Study 2017. <i>BMC Women's Health</i> , 2021, 21, 419.	0.8	14
464	Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 33.	1.7	17
465	Male Circumcision and Genital Human Papillomavirus (HPV) Infection in Males and Their Female Sexual Partners: Findings From the HPV Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 1184-1194.	1.9	2
466	AIB1 is a novel target of the high-risk HPV E6 protein and a biomarker of cervical cancer progression. <i>Journal of Medical Virology</i> , 2022, 94, 3962-3977.	2.5	4
468	Cervical Cancer Screening with HPV Testing: Updates on the Recommendation. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 264-271.	0.3	4
469	Measuring school level attributable risk to support school-based HPV vaccination programs. <i>BMC Public Health</i> , 2022, 22, 822.	1.2	6
470	Factors Predicting Mothers' Intention toward Human Papilloma Virus Vaccination of Adolescents: A Cross-sectional Study Among Iranian Families.. <i>Iranian Journal of Nursing and Midwifery Research</i> , 2021, 26, 495-499.	0.2	2
471	Knowledge, attitudes and perceptions regarding human papillomavirus among university students in Hail, Saudi Arabia. <i>PeerJ</i> , 2022, 10, e13140.	0.9	5
472	An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines. <i>Clinical Drug Investigation</i> , 2022, 42, 377.	1.1	0
473	Methylparaben as a preservative in the development of a multi-dose HPV-2 vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	1
474	Knowledge, Attitudes and Behaviors of Women who have or have not had human papillomavirus vaccine in Turkey about the Virus and the vaccine. <i>Journal of Community Health</i> , 2022, , 1.	1.9	2
475	Attitudes Toward HPV Vaccination in Sweden: A Survey Study. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	11
476	Implications of Persistent HPV52 and HPV58 Positivity for the Management of Cervical Lesions. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
477	Sibling Spillovers and the Choice to Get Vaccinated: Evidence from a Regression Discontinuity Design. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
478	OAE-Based Data Mining and Modeling Analysis of Adverse Events Associated with Three Licensed HPV Vaccines. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
479	Evidence-based circumcision policy for Australia. <i>Journal of Men's Health</i> , 2022, 18, 1.	0.1	3

#	ARTICLE	IF	CITATIONS
480	Cancer incidence and mortality and risk factors in member countries of the " Belt and Road " initiative. BMC Cancer, 2022, 22, .	1.1	7
481	EBEVEYNLERÄ°N HUMAN PAPÄ°LLOMA VÄ°RÄ°S AÄ°ZISINA YÄ°NELÄ°K BÄ°LGÄ°, TUTUM VE Ä°NANÄ±LARININ DEÄ°ZERLENDÄ°RÄ°LMESİ İLİZMİR DEMOCRACY UNIVERSITY HEALTH SCIENCES JOURNAL, 0, , .	0.4	0
482	Adult vaccine-related knowledge, attitudes, and behaviors in Turkey. Clinical and Experimental Vaccine Research, 2022, 11, 133.	1.1	0
483	Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study. Reproductive Health, 2022, 19, .	1.2	15
484	Redesign of a rapid, lowâ€cost <sc>HPV</sc> typing assay to support riskâ€based cervical screening and management. International Journal of Cancer, 2022, 151, 1142-1149.	2.3	12
485	Disparities in Human Papillomavirus vaccination coverage among adolescents in Australia: A geospatial analysis. Vaccine, 2022, 40, 4644-4653.	1.7	2
486	Association between Social Integration, Social Exclusion, and Vaccination Behavior among Internal Migrants in China: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 7915.	1.2	2
487	Assessing Attitudes and Beliefs Toward HPV Vaccination among Ghanaian Parents with Unvaccinated Adolescents: Application of Multi-Theory Model of Behavior Change. Asian Pacific Journal of Cancer Prevention, 2022, 23, 1901-1911.	0.5	1
488	Evaluating the psychometric properties of the Chinese version of the modified Carolina Human Papillomavirus immunisation attitudes and beliefs scale among Chinese adolescent girls. Preventive Medicine Reports, 2022, 28, 101902.	0.8	0
489	Risk factors and communities disproportionately affected by cervical cancer in the Russian Federation: A national population-based study. Lancet Regional Health - Europe, The, 2022, 20, 100454.	3.0	5
491	Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis. EClinicalMedicine, 2022, 52, 101585.	3.2	15
492	Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: A systematic review and meta-analysis. EClinicalMedicine, 2022, 53, 101645.	3.2	16
493	The Drivers, Mechanisms, and Consequences of Genome Instability in HPV-Driven Cancers. Cancers, 2022, 14, 4623.	1.7	8
494	A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial. Clinical Cancer Research, 2022, 28, 4885-4892.	3.2	12
495	Public health opportunities resulting from sufficient HPV vaccine supply and a single-dose vaccination schedule. Journal of the National Cancer Institute, 2023, 115, 246-249.	3.0	7
496	Prediction of the immunological and prognostic value of five signatures related to fatty acid metabolism in patients with cervical cancer. Frontiers in Oncology, 0, 12, .	1.3	2
497	Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State. Vaccines, 2022, 10, 1912.	2.1	25
498	Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1

#	ARTICLE	IF	CITATIONS
499	OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines. <i>Heliyon</i> , 2022, 8, e11515.	1.4	2
500	Cervical cancer heterogeneity: a constant battle against viruses and drugs. <i>Biomarker Research</i> , 2022, 10, .	2.8	10
501	A low-cost, paper-based hybrid capture assay to detect high-risk HPV DNA for cervical cancer screening in low-resource settings. <i>Lab on A Chip</i> , 2023, 23, 451-465.	3.1	3
502	Knowledge, attitude, and uptake of human papilloma virus vaccine and associated factors among female preparatory school students in Bahir Dar City, Amhara Region, Ethiopia. <i>PLoS ONE</i> , 2022, 17, e0276465.	1.1	11
503	Harnessing the Potential of Plant Expression System towards the Production of Vaccines for the Prevention of Human Papillomavirus and Cervical Cancer. <i>Vaccines</i> , 2022, 10, 2064.	2.1	6
504	Does Vaccination Protect against Human Papillomavirus-Related Cancers? Preliminary Findings from the United States National Health and Nutrition Examination Survey (2011â€“2018). <i>Vaccines</i> , 2022, 10, 2113.	2.1	5
506	HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	6
507	Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas. <i>Viruses</i> , 2023, 15, 141.	1.5	3
508	Progress in the development of vaccines against human papillomavirus. , 2023, , 297-316.		1
509	Raman Spectroscopy for Early Detection of Cervical Cancer, a Global Womenâ€™s Health Issueâ€™A Review. <i>Molecules</i> , 2023, 28, 2502.	1.7	7
511	Sexual Health. , 2022, , 67-118.		0
512	<sc>Circular RNA ARHGAP5</sc> inhibits cisplatin resistance in cervical squamous cell carcinoma by interacting with <sc>AUF1</sc>. <i>Cancer Science</i> , 2023, 114, 1582-1595.	1.7	3
513	Influence of online education programmes on parents' knowledge regarding human papilloma virus vaccination. <i>Indian Journal of Continuing Nursing Education</i> , 2022, 23, 164.	0.1	0
514	Projections of cancer mortality by 2025 in central China: A modeling study of global burden of disease 2019. <i>Heliyon</i> , 2023, 9, e13432.	1.4	0
515	Economic Burden of Cervical Cancer in Bulgaria. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2746.	1.2	3
516	A Single Dose, Thermostable, Trivalent Human Papillomavirus Vaccine Formulated Using Atomic Layer Deposition. <i>Journal of Pharmaceutical Sciences</i> , 2023, , .	1.6	0
517	Parental Justifications for Not Vaccinating Children or Adolescents against Human Papillomavirus (HPV). <i>Vaccines</i> , 2023, 11, 506.	2.1	0
518	Impact of COVID-19 Pandemic on Human Papillomavirus Vaccine Uptake in Israel. <i>Journal of Lower Genital Tract Disease</i> , 2023, 27, 168-172.	0.9	3

#	ARTICLE	IF	CITATIONS
519	Detection and Genotyping of Human Papillomavirus (HPV16/18), Epsteinâ€Barr Virus (EBV), and Human Cytomegalovirus (HCMV) in Endometrial Endometroid and Ovarian Cancers. <i>Pathogens</i> , 2023, 12, 397.	1.2	0
521	Knowledge, attitudes and behavior of students of the Medical College of Applied Sciences in Belgrade related to the significance of HPV infection, the HPV vaccine and other preventive measures. <i>Zdravstvena Zastita</i> , 2022, 51, 68-83.	0.0	0
522	Female adolescentsâ€™ knowledge and acceptability of human papillomavirus vaccine in Debre Tabor Town, Ethiopia: a cross-sectional study. <i>BMJ Open</i> , 2023, 13, e061813.	0.8	5
523	Formative Research on HPV Vaccine Acceptance among Health Workers, Teachers, Parents, and Social Influencers in Uzbekistan. <i>Vaccines</i> , 2023, 11, 754.	2.1	1
524	Communication strategies to improve human papillomavirus (HPV) immunisation uptake among adolescents in sub-Saharan Africa: a systematic review and meta-analysis. <i>BMJ Open</i> , 2023, 13, e067164.	0.8	2
525	Factors Associated with the Human Papillomavirus Vaccine Coverage in Gulu District, Uganda. <i>Adolescent Health, Medicine and Therapeutics</i> , 0, Volume 14, 87-96.	0.7	1
526	Human Papilloma Virus: An Unraveled Enigma of Universal Burden of Malignancies. <i>Pathogens</i> , 2023, 12, 564.	1.2	4
527	#EndtheSTigma: An Exploratory Analysis of the 2019 HPV Awareness Day Conversation on Twitter & Instagram. <i>Health Communication</i> , 0, , 1-10.	1.8	3
528	A View on Drug Development for Cancer Prevention. <i>Cancer Discovery</i> , 2023, 13, 1058-1083.	7.7	2
533	HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective. <i>VirusDisease</i> , 2023, 34, 172-190.	1.0	3
539	HPV Vaccine Misinformation Online: A Narrative Scoping Review. , 2023, , 35-55.		1
542	The Global Concern for Cancer Emergence and Its Prevention: A Systematic Unveiling of the Present Scenario. , 2023, , 1429-1455.		0
580	Clinical Management of CIN Including Recent Therapeutic Strategies. <i>Comprehensive Gynecology and Obstetrics</i> , 2024, , 99-108.	0.0	0